-
The purpose of this study is to see if cenicriviroc mesylate (or CVC) can reduce inflammation of the arteries (the…
Open and enrolling
HIV (and comorbidities)
24 weeks
-
The first study of a broadly neutralizing antibody called SAR441236 in humans, will determine if an infusion is safe and…
Closed to accrual
HIV (and comorbidities)
Most participants will be followed on study for 24 weeks after their infusion. Participants who receive multiple infusions will be followed for a total of 72 weeks.
-
A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)
This four-step study compares Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent…
Open and enrolling
HIV (and comorbidities)
Steps 1-3 combined are a total of 128 weeks. Step 4 lasts 52 weeks.
-
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…
Open and enrolling
HIV (and comorbidities)
-
A5243: Non-US Genomic Sampling
Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…
Open and enrolling
HIV (and comorbidities)
-
This study is for people with HIV who have an undetectable viral load. The study will evaluate the safety and…
Active, Not Recruiting
HIV (and comorbidities)
Participants will be on study for about 101 weeks.
-
You are being asked to take part in this research study because you are infected with HIV, the virus that…
Closed to accrual
HIV (and comorbidities)
Participants will be followed for 366 weeks (7 years).
-
In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin)…
Closed to accrual
HIV (and comorbidities)
You will be in this study for about 36 to 96 months depending on when you enroll in the study.
-
A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Aging with HIV may be associated with an earlier development of frailty (weakness) or disability, including difficulties in tests of…
Closed to accrual
HIV (and comorbidities)
Participants will be followed for 48 months from the date of enrollment into A5332. Based on their date of enrollment into A5332, participants may be followed between 24 to 48 months.
-
This is a study for people who have HIV and qualify to switch to or receive Dolutegravir containing antiretroviral therapy…
Closed to accrual
HIV (and comorbidities)
Each participant will be followed for 36 months.
-
About 30-40% of people living with HIV have a condition called NAFLD, or non-alcoholic fatty liver disease. NAFLD is caused…
Closed to accrual
HIV (and comorbidities)
-
Weight gain after starting HIV therapy is common, but recent studies have found that some people with HIV (PWH) who…
Open and enrolling
HIV (and comorbidities)
Participants will be on study treatment for 48 weeks.
